TW-37

1 1

Selleck Chemicals

S1121-10MG

€157,00 EUR
€157,00 EUR
Sale Sold out
Taxes included. Shipping calculated at checkout.
Size
View full details

TW-37 is an inhibitor of BCL-2 used in studies of Apoptosis. In practice, this places the compound in experiments that measure caspase-associated cell-death signaling and survival decisions in apoptosis and cancer models.

By inhibiting BCL-2, TW-37 can be used to examine caspase-associated cell-death signaling and survival decisions. This context is compatible with apoptosis, viability, and caspase-readout assays, as well as transcriptional, biochemical, or phenotypic comparisons linked to the annotated pathway state. In apoptosis and cancer models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

  • Target-focused assays involving BCL-2
  • Pathway perturbation studies connected to Apoptosis
  • Concentration-response inhibition and target-dependence studies
  • Phenotypic profiling in apoptosis and cancer models

Overall, TW-37 is appropriate when a defined chemical perturbant is needed to connect BCL-2 with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis and cancer models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.

Targets:
BCL-2
Target Class:
Other
Pathways:
Apoptosis
Research Area:
Apoptosis • Cancer
CAS No.:
877877-35-5
Molecular Weight:
573.7
Formula:
C₃₃H₃₅NO₆S
SMILES:
CC(C)C1=CC=CC=C1CC2=CC(=C(C(=C2O)O)O)C(=O)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=CC=C4C(C)(C)C
Storage Temperature:
-20°C

For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.

The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.